|
ES2524922T3
(es)
|
2005-05-10 |
2014-12-15 |
Intermune, Inc. |
Derivados de piridona para modular el sistema de proteína cinasa activada por estrés
|
|
HUE030390T2
(en)
|
2005-12-21 |
2017-05-29 |
Janssen Pharmaceutica Nv |
Triazolopyridazines as tyrosine kinase modulators
|
|
JP2009538899A
(ja)
*
|
2006-05-30 |
2009-11-12 |
ファイザー・プロダクツ・インク |
トリアゾロピリダジン誘導体
|
|
CA2656825C
(en)
*
|
2006-06-22 |
2013-12-10 |
Prana Biotechnology Limited |
Method of treatment and agents useful for same
|
|
US8217177B2
(en)
|
2006-07-14 |
2012-07-10 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
|
US8198448B2
(en)
|
2006-07-14 |
2012-06-12 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
|
PE20080403A1
(es)
*
|
2006-07-14 |
2008-04-25 |
Amgen Inc |
Derivados heterociclicos fusionados y metodos de uso
|
|
CA2657931A1
(en)
*
|
2006-07-18 |
2008-01-24 |
Cytovia, Inc. |
3-aryl-6-aryl-7h-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines and analogs as activators of caspases and inducers of apoptosis and the use thereof
|
|
US7683060B2
(en)
|
2006-08-07 |
2010-03-23 |
Incyte Corporation |
Triazolotriazines as kinase inhibitors
|
|
US8481538B2
(en)
|
2006-09-18 |
2013-07-09 |
Vertex Pharmaceuticals Incorporated |
Heterocyclic inhibitors of c-Met and uses thereof
|
|
ME02372B
(me)
|
2006-11-22 |
2016-06-20 |
Incyte Holdings Corp |
Imidazotriazini i imidazopiramidini kao inhibitori kinaze
|
|
PE20090188A1
(es)
|
2007-03-15 |
2009-03-20 |
Novartis Ag |
Compuestos heterociclicos como moduladores de la senda de hedgehog
|
|
CA2688823A1
(en)
*
|
2007-05-21 |
2008-11-27 |
Sgx Pharmaceuticals, Inc. |
Heterocyclic kinase modulators
|
|
DE102007026341A1
(de)
|
2007-06-06 |
2008-12-11 |
Merck Patent Gmbh |
Benzoxazolonderivate
|
|
WO2009005675A1
(en)
*
|
2007-06-28 |
2009-01-08 |
Abbott Laboratories |
Novel triazolopyridazines
|
|
DE102007032507A1
(de)
|
2007-07-12 |
2009-04-02 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
PA8792501A1
(es)
*
|
2007-08-09 |
2009-04-23 |
Sanofi Aventis |
Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
|
|
FR2919870B1
(fr)
*
|
2007-08-09 |
2014-05-16 |
Sanofi Aventis |
Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzothiazole et benzimidazole, procede, compositions pharmaceutiques et nouvelle utilisation comme inhibiteurs de cmet
|
|
FR2929613B1
(fr)
*
|
2008-04-02 |
2010-12-31 |
Sanofi Aventis |
Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole,leur preparation,comme medicaments et utilisation notamment comme inhibiteurs de met
|
|
HRP20151128T1
(hr)
|
2007-09-27 |
2015-11-20 |
Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii |
Imidazolotiadiazoli za uporabu kao inhibitori protein kinaze
|
|
DE102007061963A1
(de)
|
2007-12-21 |
2009-06-25 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
PE20091468A1
(es)
|
2008-02-28 |
2009-10-22 |
Novartis Ag |
DERIVADOS DE 3-METIL-IMIDAZO-[1,2-b]-PIRIDAZINA
|
|
DE102008019907A1
(de)
|
2008-04-21 |
2009-10-22 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
WO2009143211A2
(en)
*
|
2008-05-21 |
2009-11-26 |
Incyte Corporation |
Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
|
|
CA2726588C
(en)
|
2008-06-03 |
2019-04-16 |
Karl Kossen |
Compounds and methods for treating inflammatory and fibrotic disorders
|
|
DE102008028905A1
(de)
|
2008-06-18 |
2009-12-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
|
|
US20100041663A1
(en)
|
2008-07-18 |
2010-02-18 |
Novartis Ag |
Organic Compounds as Smo Inhibitors
|
|
DE102008037790A1
(de)
|
2008-08-14 |
2010-02-18 |
Merck Patent Gmbh |
Bicyclische Triazolderivate
|
|
UY32049A
(es)
|
2008-08-14 |
2010-03-26 |
Takeda Pharmaceutical |
Inhibidores de cmet
|
|
DE102008038220A1
(de)
|
2008-08-18 |
2010-02-25 |
Merck Patent Gmbh |
Oxadiazolderivate
|
|
DE102008038222A1
(de)
|
2008-08-18 |
2010-02-25 |
Merck Patent Gmbh |
Indazol-5-carbonsäurehydrazid-derivate
|
|
DE102008038221A1
(de)
|
2008-08-18 |
2010-02-25 |
Merck Patent Gmbh |
7-Azaindolderivate
|
|
NZ592825A
(en)
*
|
2008-11-19 |
2013-01-25 |
Vertex Pharma |
A triazolothiadiazole inhibitor of c-met protein kinase
|
|
JP2012509342A
(ja)
|
2008-11-20 |
2012-04-19 |
オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド |
置換ピロロ［２，３−ｂ］−ピリジンおよび−ピラジン
|
|
PA8851101A1
(es)
|
2008-12-16 |
2010-07-27 |
Lilly Co Eli |
Compuesto amino pirazol
|
|
DE102008063667A1
(de)
|
2008-12-18 |
2010-07-01 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate
|
|
MY160526A
(en)
|
2008-12-22 |
2017-03-15 |
Merck Patent Gmbh |
Novel polymorphic forms of 6-(1-methyl-1h-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2h-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof
|
|
DE102008062825A1
(de)
|
2008-12-23 |
2010-06-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate
|
|
FR2941951B1
(fr)
*
|
2009-02-06 |
2011-04-01 |
Sanofi Aventis |
Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
|
|
FR2941952B1
(fr)
*
|
2009-02-06 |
2011-04-01 |
Sanofi Aventis |
Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
|
|
FR2941949B1
(fr)
*
|
2009-02-06 |
2011-04-01 |
Sanofi Aventis |
Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met.
|
|
FR2941950B1
(fr)
*
|
2009-02-06 |
2011-04-01 |
Sanofi Aventis |
Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
|
|
ES2427917T3
(es)
|
2009-02-10 |
2013-11-04 |
Astrazeneca Ab |
Derivados de triazolo [4,3-b] piridazina y sus usos para el cáncer de próstata
|
|
US8865719B2
(en)
|
2009-03-09 |
2014-10-21 |
The Regents Of The University Of California |
Substituted heterocycles and their use as allosteric modulators of nicotinic and GABAA receptors
|
|
US8815918B2
(en)
|
2009-04-02 |
2014-08-26 |
Centro Nacional De Investigaciones Oncologicas (Cnio) |
Imidazo [2, 1-B] [1, 3, 4] thiadiazole derivatives
|
|
CA2762186A1
(en)
*
|
2009-05-28 |
2010-12-02 |
Vertex Pharmaceuticals Incorporated |
Substituted pyrazole inhibitors of c-met protein kinase
|
|
CN102448969A
(zh)
*
|
2009-05-28 |
2012-05-09 |
沃泰克斯药物股份有限公司 |
C-met蛋白激酶抑制剂
|
|
RU2552993C2
(ru)
*
|
2009-05-28 |
2015-06-10 |
Вертекс Фармасьютикалз Инкорпорейтед |
Аминопиразол триазолотиадиазольные ингибиторы протеинкиназы с-мет
|
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
|
UA108618C2
(uk)
*
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
|
JP5781510B2
(ja)
|
2009-08-12 |
2015-09-24 |
ノバルティス アーゲー |
ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用
|
|
JP5775871B2
(ja)
|
2009-08-20 |
2015-09-09 |
ノバルティス アーゲー |
ヘテロ環式オキシム化合物
|
|
EP3795573B1
(en)
|
2009-12-31 |
2022-07-06 |
Hutchison Medipharma Limited |
Certain triazolopyrazines, compositions thereof and methods of use therefor
|
|
EA025304B1
(ru)
|
2010-02-03 |
2016-12-30 |
Инсайт Холдингс Корпорейшн |
ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИНЫ В КАЧЕСТВЕ c-Met ИНГИБИТОРОВ
|
|
WO2011143646A1
(en)
|
2010-05-14 |
2011-11-17 |
OSI Pharmaceuticals, LLC |
Fused bicyclic kinase inhibitors
|
|
AR081039A1
(es)
|
2010-05-14 |
2012-05-30 |
Osi Pharmaceuticals Llc |
Inhibidores biciclicos fusionados de quinasa
|
|
JP5960688B2
(ja)
|
2010-05-17 |
2016-08-02 |
インコゼン セラピューティクス プライベート リミテッド |
プロテインキナーゼ調節物質としての新規３，５−二置換−３ｈ−［１，２，３］トリアゾロ［４，５−ｂ］ピリジン化合物
|
|
JP2013527195A
(ja)
*
|
2010-05-27 |
2013-06-27 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
ｃ−Ｍｅｔプロテインキナーゼのアミノピラゾールトリアゾロチアジアゾールインヒビター
|
|
US20130315895A1
(en)
|
2010-07-01 |
2013-11-28 |
Takeda Pharmaceutical Company Limited |
COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
|
|
AR085183A1
(es)
*
|
2010-07-30 |
2013-09-18 |
Lilly Co Eli |
Compuesto 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-iltio)-[1,2,4]triazol[4,3-b]piridazina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar cancer
|
|
EP2710003A1
(en)
|
2011-05-16 |
2014-03-26 |
OSI Pharmaceuticals, LLC |
Fused bicyclic kinase inhibitors
|
|
MD20140044A2
(ro)
|
2011-11-11 |
2014-08-31 |
Pfizer Inc. |
2-Tiopirimidinone şi utilizarea lor pentru tratamentul afecţiunilor cardiovasculare
|
|
WO2013134562A1
(en)
|
2012-03-09 |
2013-09-12 |
Inception 2, Inc. |
Triazolone compounds and uses thereof
|
|
KR20140138293A
(ko)
|
2012-03-16 |
2014-12-03 |
액시킨 파마수티컬스 인코포레이티드 |
3,5-다이아미노피라졸 키나아제 억제제
|
|
EP2831073B1
(en)
|
2012-03-30 |
2020-12-09 |
Rhizen Pharmaceuticals S.A. |
Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b]pyridine compounds as modulators of c-met protein kinases
|
|
AR092742A1
(es)
|
2012-10-02 |
2015-04-29 |
Intermune Inc |
Piridinonas antifibroticas
|
|
AU2013363398B2
(en)
|
2012-12-20 |
2017-06-01 |
Tempest Therapeutics, Inc. |
Triazolone compounds and uses thereof
|
|
US9776976B2
(en)
|
2013-09-06 |
2017-10-03 |
Inception 2, Inc. |
Triazolone compounds and uses thereof
|
|
NZ631142A
(en)
|
2013-09-18 |
2016-03-31 |
Axikin Pharmaceuticals Inc |
Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
|
|
DK3053923T3
(en)
|
2013-09-30 |
2018-07-23 |
Korea Res Inst Chemical Tech |
TRIAZOLOPYRAZINE DERIVATIVES AS TYROSIN KINASE INHIBITORS
|
|
GB201321745D0
(en)
*
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic agents
|
|
MX382781B
(es)
|
2014-04-02 |
2025-03-13 |
Intermune Inc |
Piridinonas anti-fibroticas.
|
|
JP6864953B2
(ja)
|
2014-12-09 |
2021-04-28 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Ａｘｌに対するヒトモノクローナル抗体
|
|
US9546163B2
(en)
|
2014-12-23 |
2017-01-17 |
Axikin Pharmaceuticals, Inc. |
3,5-diaminopyrazole kinase inhibitors
|
|
WO2016135041A1
(en)
|
2015-02-26 |
2016-09-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fusion proteins and antibodies comprising thereof for promoting apoptosis
|
|
EP3285764B1
(en)
*
|
2015-03-31 |
2024-03-27 |
University of Vermont and State Agricultural College |
Triazolopyridazines for treating cryptosporidiosis
|
|
AU2016257179A1
(en)
|
2015-05-05 |
2017-11-02 |
Pfizer Inc. |
2-thiopyrimidinones
|
|
MA42266A
(fr)
|
2015-06-25 |
2018-05-02 |
Taiho Pharmaceutical Co Ltd |
Agent thérapeutique contre la fibrose
|
|
LT3319959T
(lt)
|
2015-07-06 |
2021-12-27 |
Alkermes, Inc. |
Histono deacetilazės hetero-halogeno inhibitoriai
|
|
EP3319968A1
(en)
|
2015-07-06 |
2018-05-16 |
Rodin Therapeutics, Inc. |
Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
|
|
KR102707502B1
(ko)
|
2015-10-14 |
2024-09-13 |
브리스톨-마이어스 스큅 컴퍼니 |
Apj 효능제로서의 2,4-디히드록시-니코틴아미드
|
|
UY37005A
(es)
|
2015-12-04 |
2017-06-30 |
Bristol-Myers Squibb Company Una Corporacion Del Estado De Delaware |
Hidroxipirimidinonas sustituidas como agonistas del receptor de apelina y sus usos
|
|
BR112018012112A2
(pt)
|
2015-12-16 |
2018-12-04 |
Bristol-Myers Squibb Company |
heteroaril-hidroxipirimidinonas como agonistas do receptor apj
|
|
TWI744301B
(zh)
|
2016-03-24 |
2021-11-01 |
美商必治妥美雅史谷比公司 |
做為apj促效劑之6-羥基-4-側氧-1,4-二氫嘧啶-5-甲醯胺
|
|
GR1009565B
(el)
|
2016-07-14 |
2019-08-06 |
Galenica Α.Ε. |
Νεα παραγωγα 1,2,4-τριαζολο-[3,4-b]-1,3,4-θειαδιαζολιων
|
|
RS62959B1
(sr)
|
2017-01-11 |
2022-03-31 |
Alkermes Inc |
Biciklični inhibitori histon-deacetilaze
|
|
HUE068810T2
(hu)
|
2017-02-15 |
2025-01-28 |
Taiho Pharmaceutical Co Ltd |
Gyógyászati készítmény
|
|
EP3632904B1
(en)
*
|
2017-05-26 |
2022-04-20 |
Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd. |
Urat1 inhibitors for promoting uric acid excretion
|
|
JP7234201B2
(ja)
*
|
2017-07-12 |
2023-03-07 |
ブリストル－マイヤーズ スクイブ カンパニー |
心不全の治療のためのｒｏｃｋの５員アミノヘテロ環および５，６－または６，６員二環式アミノヘテロ環の阻害剤
|
|
US11225475B2
(en)
|
2017-08-07 |
2022-01-18 |
Alkermes, Inc. |
Substituted pyridines as inhibitors of histone deacetylase
|
|
MA50251A
(fr)
|
2017-09-08 |
2021-06-02 |
Taiho Pharmaceutical Co Ltd |
Agent antitumoral et potentialisateur d'effet antitumoral
|
|
KR20200143376A
(ko)
|
2018-03-13 |
2020-12-23 |
샤이어 휴먼 지네틱 테라피즈 인크. |
혈장 칼리크레인 억제제로서의 치환된 이미다조피리딘 및 이의 용도
|
|
CN114667289B
(zh)
|
2019-09-18 |
2025-08-26 |
武田药品工业有限公司 |
杂芳基血浆激肽释放酶抑制剂
|
|
EP4031547B1
(en)
|
2019-09-18 |
2024-07-17 |
Takeda Pharmaceutical Company Limited |
Plasma kallikrein inhibitors and uses thereof
|
|
TR202009388A1
(tr)
|
2020-06-17 |
2021-12-21 |
Anadolu Ueniversitesi |
Akci̇ğer kanseri̇ tedavi̇si̇nde hedefe yöneli̇k yeni̇ tri̇azoloti̇yadi̇azi̇n türevleri̇
|
|
TR202010296A1
(tr)
|
2020-06-30 |
2022-01-21 |
Anadolu Ueniversitesi |
Akt inhibisyonu aracılığıyla a549 hücrelerinde sitotoksik ve apoptotik etki gösteren yeni triazol ve triazolotiyadiazin türevleri
|
|
JP2024506858A
(ja)
|
2021-02-02 |
2024-02-15 |
リミナル・バイオサイエンシーズ・リミテッド |
Ｇｐｒ８４アンタゴニストおよびその使用
|
|
EP4308564A1
(en)
*
|
2021-03-17 |
2024-01-24 |
Takeda Pharmaceutical Company Limited |
Polycyclic inhibitors of plasma kallikrein
|